Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.

Miguel Ángel Rubio-HerreraSara Mera-CarreiroAndrés Sánchez-PernauteAna M Ramos-Levi

Published in: Biomedicines (2023)

Losing >15% of initial weight after 52 weeks of treatment with liraglutide 3.0 mg or semaglutide 1.0 mg during the waiting list for MBS impacts patients' decisions regarding the final acceptance or rejection of the procedure.

Keyphrases

bariatric surgery
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
physical activity
peritoneal dialysis
minimally invasive
prognostic factors
combination therapy
weight gain
body weight
patient reported